This research presents a novel high-throughput yeast display platform designed to engineer fast-acting covalent protein drugs that overcome the limitations of rapid systemic clearance. By integrating site-specific chemical crosslinkers with precise protein mutations, the authors successfully developed IB101, a potent PD-L1 antagonist, and IB201, a covalent IL-18 agonist. These engineered proteins ...去小宇宙查看完整单集简介
前往小宇宙评论区与主播互动